Jarno Hoekman
Jarno Hoekman
Innovation Studies Group, Utrecht University
Verifierad e-postadress på uu.nl - Startsida
Citeras av
Citeras av
Research collaboration at a distance: Changing spatial patterns of scientific collaboration within Europe
J Hoekman, K Frenken, RJW Tijssen
Research Policy 39 (5), 662-673, 2010
The geography of collaborative knowledge production in Europe
J Hoekman, K Frenken, F Van Oort
The annals of regional science 43 (3), 721-738, 2009
Spatial scientometrics: Towards a cumulative research program
K Frenken, S Hardeman, J Hoekman
Journal of informetrics 3 (3), 222-232, 2009
Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis
HJL Heerspink, TF Kröpelin, J Hoekman, D De Zeeuw
Journal of the American Society of Nephrology 26 (8), 2055-2064, 2015
Big Pharma, Little Science? A bibliometric perspective on big pharma’s R&D decline
I Rafols, M Hopkins, J Hoekman, P Nightingale, A Perianes-Rodriguez, ...
Technological Forecasting and Social Change, 2012
Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous …
HH Ampadu, J Hoekman, ML de Bruin, SN Pal, S Olsson, D Sartori, ...
Drug Safety 39 (4), 335-345, 2016
Acquisition of European research funds and its effect on international scientific collaboration
J Hoekman, T Scherngell, K Frenken, R Tijssen
Journal of economic geography 13 (1), 23-52, 2013
What drives university research performance? An analysis using the CWTS Leiden Ranking data
K Frenken, GJ Heimeriks, J Hoekman
Journal of informetrics 11 (3), 859-872, 2017
Challenges in advanced therapy medicinal product development: a survey among companies in Europe
RMT Ten Ham, J Hoekman, AM Hövels, AW Broekmans, HGM Leufkens, ...
Molecular Therapy-Methods & Clinical Development 11, 121-130, 2018
Death of distance in science? A gravity approach to research collaboration
K Frenken, J Hoekman, S Kok, R Ponds, F Oort, J Vliet
Innovation networks, 43-57, 2009
Use of the conditional marketing authorization pathway for oncology medicines in Europe
J Hoekman, WPC Boon, JC Bouvy, HC Ebbers, JP de Jong, ML De Bruin
Clinical Pharmacology & Therapeutics 98 (5), 534-541, 2015
Convergence in an enlarged Europe: the role of network cities
K Frenken, J Hoekman
Tijdschrift voor economische en sociale geografie 97 (3), 321-326, 2006
Characteristics and follow‐up of postmarketing studies of conditionally authorized medicines in the EU
J Hoekman, TT Klamer, AK Mantel‐Teeuwisse, HGM Leufkens, ...
British journal of clinical pharmacology 82 (1), 213-226, 2016
The Geographical Distribution of Leadership in Globalized Clinical Trials
J Hoekman, K Frenken, D de Zeeuw, HL Heerspink
PLOS ONE 7 (10), e45984, 2012
The geography of scientific citations
ML Wuestman, J Hoekman, K Frenken
Research Policy 48 (7), 1771-1780, 2019
Spatial scientometrics and scholarly impact: A review of recent studies, tools, and methods
K Frenken, J Hoekman
Measuring scholarly impact, 127-146, 2014
EU decision-making for marketing authorization of advanced therapy medicinal products: a case study
S de Wilde, DGM Coppens, J Hoekman, ML de Bruin, HGM Leufkens, ...
Drug Discovery Today 23 (7), 1328-1333, 2018
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers
B Schievink, D De Zeeuw, PA Smink, D Andress, JJ Brennan, B Coll, ...
European journal of preventive cardiology 23 (7), 758-768, 2016
Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?
I Lipska, J Hoekman, N McAuslane, HGM Leufkens, AM Hövels
Clinical Pharmacology & Therapeutics 98 (5), 489-491, 2015
Collaboration networks as carriers of knowledge spillovers
J Hoekman, K Frenken, F Van Oort
KITeS Working Papers 222, 2008
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20